Last reviewed 2026-04-19 · How we verify

PF-06412562

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia (PHASE2)
• Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals (PHASE1)
• PF 06412562 in Subjects With Advanced Stage Parkinson's Disease (PHASE1)
• D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 (EARLY_PHASE1)
• A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia (PHASE1)
• A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males (PHASE1)
• A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions (PHASE1)
• Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.